Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KUR-212 in Burn Patients Undergoing Skin Grafting
NCT00471939Phase 2Completed
- Sponsor
- Kuros Biosciences
- Start
- Apr 2007
- Primary completion
- Dec 2007
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of KUR-212 in burn injury (2 arms), sponsored by Kuros Biosciences. Primary endpoint: Incidence of treatment-related adverse events at 28 days. Started Apr 2007; status: completed.
02
Drugs
KUR-212
03
Conditions
burn injury
Beyond the preview
Go deeper on NCT00471939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00471939.